AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02208050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01486186
Drug: placebo chinese medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
Trial: NCT00461097
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for egg white solid
Trial: NCT03951753
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02801981
Drug: GSK2230672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.
Trial: NCT02801981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672
Trial: NCT00496704
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01741155
Drug: SPI-1620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPI-1620 11 μg/m2 administered intravenously over one minute.
Trial: NCT03996564
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500mg-1000mg,
Trial: NCT03996564
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac 50mg-75 mg orally
Trial: NCT03996564
Drug: Hydrocodone
RxNorm normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocodone 5mg/325mg-10mg/650mg mg
Trial: NCT03996564
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, or intramuscular Ketorolac 30mg-60 mg
Trial: NCT01483599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injections
Trial: NCT02771860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical syringe
Trial: NCT00618124
Drug: SU011248; Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
Trial: NCT00562731
Drug: ARD-0403
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily transdermal ARD-0403
Trial: NCT03678675
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention is a protocol of scheduled IV Ketorolac administered postoperatively.
Trial: NCT02686788
Drug: TMP001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
Trial: NCT01681095
Drug: Custodiol HTK
RxNorm normalized name: CUSTODIOL HTK SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 10°C.
Trial: NCT01681095
Drug: Cold Blood Cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional \> 200 mL was administered in an antegrade/retrograde fashion throughout the remainder of the case. The cardioplegic solution was delivered at a temperature of 4°C - 8°C.
Trial: NCT00564278
Drug: Standard antidepressant therapy (SADT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).
Trial: NCT03758235
Drug: IncobotulinumtoxinA 100 UNT Injection [Xeomin]
RxNorm normalized name: incobotulinumtoxinA 100 UNT Injection [Xeomin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incobot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
Trial: NCT03758235
Drug: OnabotulinumtoxinA 100 UNT [Botox]
RxNorm normalized name: onabotulinumtoxinA 100 UNT [Botox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onabot/A intradetrusor injections under cystscopic guidance, with local anaethesia in an outpatient basis
Trial: NCT03332095
Drug: Antiretroviral (ARV) medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in Cohort 1 received a combination of dolutegravir (DTG) or raltegravir (RAL) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The ARV drugs were prescribed by participants' own health care providers and were not provided by the study.
Trial: NCT03900572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection, 3 doses
Trial: NCT04582201
Drug: agenT-797
RxNorm normalized name: MISCELLANEOUS AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Trial: NCT02290925
Drug: Kothala Himbutu Biscuit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kothala Himbutu biscuit (containing Salacia reticulata extract) as a snack. This herb has been used by traditional physicians to control blood sugar.
Trial: NCT03688802
Drug: OC-01 (varenicline) nasal spray
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC-01 (varenicline) nasal spray
Trial: NCT03688802
Drug: Placebo (vehicle control) nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01633970
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive leucovorin 400 mg/m\^2 IV q2w.
Trial: NCT00253370
Drug: BAY 43-9006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01410240
Drug: FLOSEAL Hemostatic Matrix + Standard of care
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.~+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used
Trial: NCT03699540
Drug: placebo alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental, non-therapeutic administration of inactive alcohol dose(s)
Trial: NCT01489852
Drug: 17beta-estradiol
RxNorm normalized name: 16alpha-(18F)Fluoro-17beta-estradiol
DrugBank: Fluoroestradiol F-18 (DB15690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
Trial: NCT04728984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two placebo pills; Oral administration after dinner, once daily for 14 consecutive days
Trial: NCT04691687
Drug: IV Solution
RxNorm normalized name: IV SOLUTIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Placebo comparator
Trial: NCT00079885
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03522207
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo per os 30 minutes prior to 2nd PSG
Trial: NCT03522207
Drug: placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg placebo per os 30 minutes prior to 3rd PSG
Trial: NCT03385551
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol or Promestriene depending on the arm
Trial: NCT04242407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching patches that have no active drug applied before surgery and worn for 96 hours
Trial: NCT01474161
Drug: GFT505 120mg - old formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
Trial: NCT01474161
Drug: GFT505 180mg - new formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
Trial: NCT01474161
Drug: GFT505 240mg - new formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
Trial: NCT01474161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
Trial: NCT00884793
Drug: Study NNRTI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).
Trial: NCT01324128
Drug: PA21 (2.5 g tablet containing 500 mg iron)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
Trial: NCT02611765
Drug: Benzathine penicillin G intramuscular 7.2 million units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
Trial: NCT02611765
Drug: Benzathine penicillin G intramuscular 2.4 million units
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of intramuscular 2.4 million units of benzathine penicillin G
Trial: NCT00230984
Drug: Oral dietary supplements (563 kcal/d), RESPIFOR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00230984
Drug: 160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00884793
Drug: Study PI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
Trial: NCT02794506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules was taken by the control group for 6 months after receiving scaling and root planing (SRP).
Trial: NCT00964405
Drug: GSK233705
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Long acting muscarinic receptor antagonist
Trial: NCT00964405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02591030
Drug: GEMCIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At D1 and D8 of each cycle, i.e. every 21 days for 6 months:~* Cisplatin 25 mg/m² over 1 hour at D1 and D8~* Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8.
Trial: NCT02591030
Drug: mFolfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At D1 of each cycle, i.e. every 15 days for 6 months:~* Oxiplatin: 85 mg/m² (IP/120 minutes)~* Irinotecan: 180 mg/m² (IV/90 minutes)~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine \[calcium levofolinate\]) (IV/2 hours), via a Y connector at the same time as irinotecan~* 5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1
Trial: NCT01324128
Drug: PA21-1 (1.25 g tablet containing 250 mg iron)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose comparator (1.25 g/day)
Trial: NCT00040144
Drug: ACH126, 433
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02984644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.
Trial: NCT02829385
Drug: Apatinib and XELOX combined treatment group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs.
Trial: NCT00311753
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
Trial: NCT02009423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00048165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered on Days 1, 8, 22, 36, and 50.
Trial: NCT02282163
Drug: sulphur hexafluoride lipid-type A microspheres
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound imaging contrast agent
Trial: NCT00426972
Drug: estradiol (Zesteem)
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004896
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01812616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs \& Cosmetics (FD\&C)certified color additives; FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
Trial: NCT01627795
Drug: Oshadi D and Oshadi R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti cancer agents
Trial: NCT04598295
Drug: DS-01
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: synbiotic
Trial: NCT03485703
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the newborn group will receive intravenous azithromycin 10 mg / kg / day once daily for 5 days
Trial: NCT03485703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the group of newborns will receive 0.9% saline once daily for 5 days
Trial: NCT00802958
Drug: Halobetasol Propionate 0.05% Ointment-Reference Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small amount applied and evaluated over the course of a day
Trial: NCT00802958
Drug: Halobetasol Propionate 0.05% Ointment-Test Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small amount applied and evaluated over the course of a day
Trial: NCT02787083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00182533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 - 200 mg/day x 16 weeks
Trial: NCT00003513
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT00312052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg and/or 100 mg placebo tablets
Trial: NCT00652717
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
Trial: NCT02547896
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients will receive only diclofenac
Trial: NCT01612078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg/tab, po, three times a week.
Trial: NCT03277716
Drug: Chemoembolization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin. Embolic agent: lipiodol and embolic microspherea The mixture solution containing chemotherapeutic drugs and embolic agent were infused into the artery according to by the number and size of the lesions, liver and kidney function of the patient, and blood supply of the tumors.
Trial: NCT03891823
Drug: Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be randomized to medical therapy to determine treatment efficacy in improving LV remodelling or functional capacity.
Trial: NCT02735473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00857961
Drug: Testosterone MD-Lotion
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered Topically
Trial: NCT02226120
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
Trial: NCT04272957
Drug: HMPL-306
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-306 administered continuously as a single agent starting at 25 mg orally every day in a 28-day cycle and dose escalation is planned up to 200mg. Subjects may continue treatment with HMPL-306 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
Trial: NCT03285165
Drug: 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.
Trial: NCT04418089
Drug: Simvastatin 40mg
RxNorm normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The administration of Simvastatin 40 mg in addition to neoadjuvant chemoterapy CAF
Trial: NCT04418089
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of Placebo capsule 40 mg in addition to neoadjuvant chemoterapy CAF
Trial: NCT01905592
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choice of 4 standard of care metastatic breast cancer chemotherapies, until progression or unacceptable toxicity develops
Trial: NCT03034135
Drug: Disulfiram/Copper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram/copper gluconate is taken three times a day.
Trial: NCT01897519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion
Trial: NCT02859519
Drug: MOB015B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOB015B - Terbinafine hydrochloride (HCl) 10%, topical solution
Trial: NCT02859519
Drug: MOB015B Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOB015B Vehicle without the active ingredient Terbinafine
Trial: NCT04137341
Drug: GLPG1972 - A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet, formulation A
Trial: NCT04137341
Drug: GLPG1972 - B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet, formulation B
Trial: NCT02870764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Trial: NCT02530918
Drug: DS-7080a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution
Trial: NCT02324621
Drug: Oral ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00817505
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral tablet
Trial: NCT00817505
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral suspension
Trial: NCT00565097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03280745
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.